Market Overview

Exelixis Present Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer


Exelixis, Inc. (NASDAQ: EXEL) today announced the presentation of updated
interim data from 144 docetaxel-pretreated patients with metastatic
castration-resistant prostate cancer (mCRPC) and bone metastases treated
with cabozantinib in an ongoing non-randomized expansion (NRE) cohort of
its phase 2 randomized discontinuation trial. Median overall survival
was 10.8 months in a patient population in which 73% of patients had
received two or more prior therapies including docetaxel and
abiraterone, enzalutamide, and/or cabazitaxel. Furthermore, a
retrospective analysis of the interim data shows that early responses in
bone scan, circulating tumor cell (CTC) levels, and pain are associated
with longer median overall survival (OS) as compared to non-responders.
These post hoc findings, particularly the bone scan response results,

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (EXEL)

View Comments and Join the Discussion!

Partner Center